ARTICLE | Clinical News
Halaven eribulin mesylate regulatory update
February 4, 2013 8:00 AM UTC
Eisai said it submitted a regulatory application to South Africa's Medicines Control Council (MCC) for Halaven eribulin as monotherapy to treat locally advanced or metastatic breast cancer in patients...